{"id":186,"date":"2016-04-26T11:06:09","date_gmt":"2016-04-26T11:06:09","guid":{"rendered":"http:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/?p=186"},"modified":"2022-04-13T13:59:11","modified_gmt":"2022-04-13T13:59:11","slug":"scope2-can-increasing-the-dose-of-radiotherapy-improve-outcomes-in-patients-with-oesophageal-cancer","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/scope2-can-increasing-the-dose-of-radiotherapy-improve-outcomes-in-patients-with-oesophageal-cancer\/","title":{"rendered":"SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?"},"content":{"rendered":"<p><em>SCOPE2 is a randomised Phase II\/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET). SCOPE2\u00a0is a Cancer Research UK\u00a0funded trial run by the Wales Cancer Trials Unit based in the Centre for Trials Research at Cardiff University.<\/em><\/p>\n<p>Research has shown that increasing the dose of radiotherapy improves outcomes in patients with lung and head and neck cancers. The SCOPE2 study aims to see whether this is also the case for patients with tumours of the oesophagus. This trial will compare the effects of the standard dose of radiotherapy to a higher dose, whilst closely monitoring the side effects.<\/p>\n<p>A comparison will also be made regarding the effects of the standard drugs used in chemotherapy (cisplatin and capecitabine) with an alternative combination (carboplatin and paclitaxel) in patients that do not show a response to chemotherapy with standard drugs early on in treatment.<\/p>\n<p>The SCOPE2 trial incorporates a detailed radiotherapy protocol, designed by a group of dedicated clinical experts, which aims to champion the use of the new state-of-the-art radiation delivery system IMRT (intensity modulated radiation therapy) for planning oesophageal cancers at hospitals across the UK. By using IMRT, clinicians will be able to target the tumour more precisely, potentially allowing for a higher dose of radiotherapy to be delivered to the cancer whilst limiting damage to normal tissue.<\/p>\n<p>Clinicians will be asked to follow the SCOPE2 radiotherapy protocol when outlining and planning radiotherapy for SCOPE2 patients. A real time Quality Assurance review of the data will be conducted by the Radiotherapy Quality Assurance team prior to radiotherapy delivery to ensure that the protocol was followed. This has been shown in the SCOPE1 trial to significantly improve patient outcomes.<\/p>\n<p>In order to support clinicians and physicists, the SCOPE2 team organised\u00a0a radiotherapy workshop on 26\u00a0April 2016 to provide training on the protocol and Quality Assurance procedures and will also provide a platform for discussion on past and future trials.\u00a0 With 60 confirmed clinicians and physicists from around the UK attending, this was\u00a0a very productive, important and effective meeting!<\/p>\n<p>The\u00a0trial\u00a0will recruit 584 patients over 5.5 years.<\/p>\n<p>For more information, please email\u00a0the\u00a0<a href=\"mailto:SCOPE2 Trials &lt;SCOPE2@cardiff.ac.uk&gt;\" target=\"_blank\" rel=\"noopener\">SCOPE2 Trials team<\/a>.<\/p>\n<p><em>Article contributed by Dr Ruby Ray, Wales Cancer Trials Unit, Centre for Trials Research<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"SCOPE2 is a randomised Phase II\/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with [&hellip;]","protected":false},"author":1145,"featured_media":202,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[3],"tags":[48,21],"class_list":["post-186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-trial","tag-cancer","tag-radiography"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-30","jetpack-related-posts":[{"id":2693,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/world-radiography-day-2023-centre-for-trials-research-radiotherapy-trials-and-beyond\/","url_meta":{"origin":186,"position":0},"title":"World Radiography Day 2023: Centre For Trials Research Radiotherapy Trials And Beyond","author":"Sarah Bridges","date":"November 7, 2023","format":false,"excerpt":"Authors: Sarah Bridges, Christie Heiberg, Lisette Nixon, Jack Pritchard, Ann White BACKGROUND World Radiography Day marks the anniversary of the discovery of x-rays by Wilhelm Roentgen in 1895.\u00a0Soon after Roentgen\u2019s discovery, scientists began experimenting with x-rays on living tissue, learning that they were an effective method of stopping cancer cells\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2941,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/pathos-clinical-trial-exploring-de-intensification-in-head-and-neck-cancer\/","url_meta":{"origin":186,"position":1},"title":"PATHOS Clinical Trial: Exploring De-Intensification in Head and Neck Cancer","author":"Christie Heiberg","date":"July 27, 2024","format":false,"excerpt":"The PATHOS clinical trial is investigating the potential benefits of de-intensified treatment for individuals with head and neck cancer, specifically HPV-positive oropharyngeal cancer. Led by Professors Terry Jones and Mererid Evans, the trial is funded by Cancer Research UK, co-sponsored by Cardiff University and Velindre University NHS Trust and managed\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":1885,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/spotlight-on-the-pathos-study\/","url_meta":{"origin":186,"position":2},"title":"Spotlight on: The PATHOS Study","author":"Richard Haggerty","date":"August 5, 2020","format":false,"excerpt":"PATHOS is a Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer. The aim of the study is to tailor treatment for participants with HPV-positive oropharyngeal cancer to reduce side-effects, particularly swallowing problems, which have a major impact on\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":2828,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/centre-for-trials-research-at-the-wales-cancer-research-conference-2024\/","url_meta":{"origin":186,"position":3},"title":"Centre for Trials Research At The Wales Cancer Research Conference 2024","author":"Angela Casbard","date":"March 21, 2024","format":false,"excerpt":"In early March, several Centre for Trials Research (CTR) staff members attended the Wales Cancer Research Conference 2024 at the National Museum, Cardiff. The conference brought together cancer researchers and other stakeholders across Wales and beyond to showcase their research successes and foster new collaborations. Centre for Trials Research Cancer\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"Cancer Division Photo at the Wales Cancer Centre Conference in March 2024.","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2749,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/advancements-in-aml-treatment-insights-from-the-aml18-trial\/","url_meta":{"origin":186,"position":4},"title":"Advancements in AML Treatment: Insights from the AML18 Trial","author":"Richard Haggerty","date":"November 30, 2023","format":false,"excerpt":"A new publication in Blood for the AML18 trial adds to research evidence to help improve patient outcomes. Acute Myeloid Leukemia (AML) represents a significant challenge in cancer care, particularly among adults where it is the most prevalent form of acute leukemia. Characterised by rapid progression, AML demands immediate and\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/AML-Blood-Cancer-Research-Team.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2734,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/faktion-and-the-breast-cancer-drug-paving-a-future-for-hormonal-therapies\/","url_meta":{"origin":186,"position":5},"title":"FAKTION And The Breast Cancer Drug Paving A Future For Hormonal Therapies","author":"Margherita Carucci","date":"November 29, 2023","format":false,"excerpt":"- by Margherita Carucci and Angela Casbard on behalf of the FAKTION CTR Team When a patient is diagnosed with cancer, their doctor will prescribe a drug or a combination of drugs for destroying or keeping the cancer cells under control. But how do doctors know which drugs are the\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/1145"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=186"}],"version-history":[{"count":11,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/186\/revisions"}],"predecessor-version":[{"id":2245,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/186\/revisions\/2245"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media\/202"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}